Is aspirin recommended for primary prevention of cardiovascular disease in adults over 60?

Current major guidelines (USPSTF 2022, ACC/AHA 2019) recommend against routine initiation of low-dose aspirin for primary prevention of CVD in adults 60 and older, largely because modest reductions in cardiovascular events in this age group are offset by increased bleeding risk; ESC guidance leaves some room for individualized use in selected high-risk patients without established ASCVD.

Guideline recommendations for adults ≥60

• The 2022 USPSTF guideline recommends against initiating low-dose aspirin for primary prevention of CVD in adults 60 years or older (Grade D)
• The 2019 ACC/AHA guideline states low-dose aspirin (75–100 mg orally daily) should not be administered on a routine basis for primary prevention of ASCVD among adults over 70 years of age
• European Society of Cardiology 2021 guidance notes that in selected patients without established ASCVD at high or very high CVD risk, the benefits of aspirin outweigh the risks, without a specific age cutoff for older adults stated in this span
• Earlier 2016 ESC guidance recommended against antiplatelet therapy in individuals without CVD (Class III, Level B) due to increased bleeding risk

Evidence on aspirin efficacy in older adults

• Guideline documents describe that the 2022 USPSTF's lowered recommendation was primarily driven by three recent trials demonstrating neutral or only modest benefit with aspirin use
• A meta-analysis notes that prior meta-analytic findings report a modest benefit for selected high-risk patients, mostly related to a small absolute reduction in non-fatal myocardial infarctions in elderly patients, which is offset by an increased risk of major gastrointestinal and hemorrhagic stroke

Harms of aspirin in this population

• Antiplatelet therapy is not recommended in individuals without CVD due to the increased risk of bleeding, per 2016 European guidelines
• A meta-analysis found that the modest reduction in non-fatal MI seen in elderly patients on aspirin is offset by increased risk of major gastrointestinal and hemorrhagic stroke

Sources

• Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease — American Journal of Preventive Cardiology
• Contemporary use of coronary artery calcium for the allocation of aspirin in light of the 2022 USPSTF guideline recommendations — American Journal of Preventive Cardiology
• Aspirin Colorectal Cancer Prevention in Lynch Syndrome: Recommendations in the Era of Precision Medicine † — Genes
• Eligibility of real-world patients for aspirin primary prevention trials in cardiovascular disease — BMC Medicine
• Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review — International Journal of Environmental Research and Public Health
• Aspirin for primary prevention of stroke in individuals without cardiovascular disease—A meta-analysis — International Journal of Stroke
• Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups — BMC Medicine
• Aspirin for primary prevention of cardiovascular disease — Thrombosis Journal
• A Review of National Level Guidelines for Risk Management of Cardiovascular and Diabetic Disease — Cureus
• Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018 — Scientific Reports
• Aspirin: Pharmacology and Clinical Applications — Thrombosis

Decision support for clinicians, not medical advice. Answers are grounded in the published literature and every claim cites its source in the interactive view.